{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:04:20Z","timestamp":1791331460399,"version":"4.3.1"},"reference-count":293,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Quebec Health Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.gene.2026.150216","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:09:42Z","timestamp":1778861382000},"page":"150216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Renal Cell Carcinoma: Histopathology, Molecular Features, and the Emerging Role of Organoid Models"],"prefix":"10.1016","volume":"1003","author":[{"given":"Arantxa Karam","family":"Coppola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Shahini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohreh","family":"Mehrjoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreeharsha","family":"Tarikere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Tanguay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser","family":"Riazalhosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gene.2026.150216_b0005","unstructured":"World Cancer Research F. Kidney cancer statistics [updated 2025\/09\/07. Available from: https:\/\/www.wcrf.org\/preventing-cancer\/cancer-statistics\/kidney-cancer-statistics\/."},{"issue":"4","key":"10.1016\/j.gene.2026.150216_b0010","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.eururo.2025.06.005","article-title":"Epidemiology of Renal Cancer: Incidence, Mortality, Survival, Genetic Predisposition, and Risk Factors","volume":"88","author":"Larcher","year":"2025","journal-title":"Eur Urol."},{"key":"10.1016\/j.gene.2026.150216_b0015","unstructured":"International Agency for Research on C. Cancer Today: Dataviz tables [updated 2025\/09\/07. Available from: https:\/\/gco.iarc.fr\/today\/en\/dataviz\/tables?mode=population&cancers=29&sexes=2."},{"key":"10.1016\/j.gene.2026.150216_b0020","unstructured":"Society AC. Key Statistics About Kidney Cancer 2026 [Available from: https:\/\/www.cancer.org\/cancer\/types\/kidney-cancer\/about\/key-statistics.html."},{"key":"10.1016\/j.gene.2026.150216_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120922","article-title":"Renal cell carcinoma management: A step to nano-chemoprevention","volume":"308","author":"Siddiqi","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.gene.2026.150216_b0030","first-page":"45","article-title":"Renal cell carcinoma: links and risks","volume":"9","author":"Kabaria","year":"2016","journal-title":"Int J Nephrol Renovasc Dis."},{"key":"10.1016\/j.gene.2026.150216_b0035","article-title":"Renal Cancer","author":"Pandey","year":"2025","journal-title":"StatPearls. Treasure Island (FL): StatPearls Publishing LLC."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0040","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.eururo.2014.04.029","article-title":"Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity","volume":"67","author":"Shuch","year":"2015","journal-title":"Eur Urol."},{"key":"10.1016\/j.gene.2026.150216_b0045","doi-asserted-by":"crossref","unstructured":"Tretiakova M. What's new in kidney tumor pathology 2022: WHO 5th edition updates. J Pathol Transl Med. 2022;56(6):383-4.","DOI":"10.4132\/jptm.2022.08.16"},{"key":"10.1016\/j.gene.2026.150216_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102558","article-title":"Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification","volume":"116","author":"Rizzo","year":"2023","journal-title":"Cancer Treat Rev."},{"issue":"4","key":"10.1016\/j.gene.2026.150216_b0055","article-title":"The WHO 2022 Classification of Renal Neoplasms (5th Edition): Salient Updates","volume":"16","author":"Goswami","year":"2024","journal-title":"Cureus."},{"issue":"3","key":"10.1016\/j.gene.2026.150216_b0060","article-title":"Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment","volume":"39","author":"Bahadoram","year":"2022","journal-title":"G Ital Nefrol."},{"issue":"4","key":"10.1016\/j.gene.2026.150216_b0065","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41581-020-00359-2","article-title":"Clear cell renal cell carcinoma ontogeny and mechanisms of lethality","volume":"17","author":"Jonasch","year":"2021","journal-title":"Nat Rev Nephrol."},{"issue":"2","key":"10.1016\/j.gene.2026.150216_b0070","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ucl.2023.01.010","article-title":"Diseases of Hereditary Renal Cell Cancers","volume":"50","author":"Iliopoulos","year":"2023","journal-title":"Urol Clin North Am."},{"issue":"5","key":"10.1016\/j.gene.2026.150216_b0075","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/cam4.110","article-title":"Racial difference in histologic subtype of renal cell carcinoma","volume":"2","author":"Olshan","year":"2013","journal-title":"Cancer Med."},{"issue":"5","key":"10.1016\/j.gene.2026.150216_b0080","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.eururo.2022.08.019","article-title":"Epidemiology of Renal Cell Carcinoma: 2022 Update","volume":"82","author":"Bukavina","year":"2022","journal-title":"Eur Urol."},{"issue":"4","key":"10.1016\/j.gene.2026.150216_b0085","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.euf.2017.01.006","article-title":"Variability of Sex Disparities in Cancer Incidence over 30 Years: The Striking Case of Kidney Cancer","volume":"4","author":"Scelo","year":"2018","journal-title":"Eur Urol Focus."},{"issue":"8","key":"10.1016\/j.gene.2026.150216_b0090","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.ccell.2023.07.006","article-title":"Chromophobe renal cell carcinoma","volume":"41","author":"Henske","year":"2023","journal-title":"Cancer Cell."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0095","article-title":"Hereditary Renal Cancer Syndromes","volume":"12","author":"Yanus","year":"2024","journal-title":"Med Sci (Basel)"},{"issue":"16","key":"10.1016\/j.gene.2026.150216_b0100","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14164059","article-title":"Epidemiology and Prevention of Renal Cell Carcinoma","volume":"14","author":"Makino","year":"2022","journal-title":"Cancers (Basel)."},{"issue":"11","key":"10.1016\/j.gene.2026.150216_b0105","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41585-023-00781-8","article-title":"Effect of smoking, hypertension and lifestyle factors on kidney cancer - perspectives for prevention and screening programmes","volume":"20","author":"Campi","year":"2023","journal-title":"Nat Rev Urol."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0110","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140522","article-title":"Tobacco smoking induces metabolic reprogramming of renal cell carcinoma","volume":"131","author":"Reigle","year":"2021","journal-title":"J Clin Invest."},{"issue":"17","key":"10.1016\/j.gene.2026.150216_b0115","doi-asserted-by":"crossref","first-page":"27892","DOI":"10.18632\/oncotarget.15841","article-title":"Consumption of fruits and vegetables and risk of renal cell carcinoma: a meta-analysis of observational studies","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0120","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3945\/ajcn.111.019364","article-title":"Large prospective investigation of meat intake, related mutagens, and risk of renal cell carcinoma","volume":"95","author":"Daniel","year":"2012","journal-title":"Am J Clin Nutr."},{"issue":"7","key":"10.1016\/j.gene.2026.150216_b0125","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/bjc.2011.343","article-title":"Meat-cooking mutagens and risk of renal cell carcinoma","volume":"105","author":"Daniel","year":"2011","journal-title":"Br J Cancer."},{"issue":"10","key":"10.1016\/j.gene.2026.150216_b0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075732","article-title":"Cruciferous vegetables intake is associated with lower risk of renal cell carcinoma: evidence from a meta-analysis of observational studies","volume":"8","author":"Zhao","year":"2013","journal-title":"PLoS One."},{"issue":"5","key":"10.1016\/j.gene.2026.150216_b0135","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1080\/01635581.2013.795980","article-title":"Cruciferous vegetables consumption and risk of renal cell carcinoma: a meta-analysis","volume":"65","author":"Liu","year":"2013","journal-title":"Nutr Cancer."},{"issue":"2","key":"10.1016\/j.gene.2026.150216_b0140","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/JU.0000000000001377","article-title":"A Systematic Review and Meta-Analysis of the Significance of Body Mass Index on Kidney Cancer Outcomes","volume":"205","author":"Kim","year":"2021","journal-title":"J Urol."},{"issue":"5","key":"10.1016\/j.gene.2026.150216_b0145","doi-asserted-by":"crossref","first-page":"E423","DOI":"10.1002\/ijc.29236","article-title":"Meat and fish consumption and the risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition","volume":"136","author":"Rohrmann","year":"2015","journal-title":"Int J Cancer."},{"key":"10.1016\/j.gene.2026.150216_b0150","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.canep.2018.07.002","article-title":"Obesity and renal cell carcinoma risk by histologic subtype: A nested case-control study and meta-analysis","volume":"56","author":"Callahan","year":"2018","journal-title":"Cancer Epidemiol."},{"issue":"5","key":"10.1016\/j.gene.2026.150216_b0155","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.juro.2013.04.130","article-title":"Risk factors for renal cell carcinoma in the VITAL study","volume":"190","author":"Macleod","year":"2013","journal-title":"J Urol."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0160","doi-asserted-by":"crossref","first-page":"8565","DOI":"10.1038\/s41598-019-45014-4","article-title":"Association between blood pressure and risk of cancer development: a systematic review and meta-analysis of observational studies","volume":"9","author":"Seretis","year":"2019","journal-title":"Sci Rep."},{"issue":"3","key":"10.1016\/j.gene.2026.150216_b0165","doi-asserted-by":"crossref","first-page":"270","DOI":"10.2337\/cd21-0013","article-title":"Association Between Diabetes and the Risk of Kidney Cancer: Systematic Review and Meta-Analysis","volume":"40","author":"Bonilla-Sanchez","year":"2022","journal-title":"Clin Diabetes."},{"issue":"4","key":"10.1016\/j.gene.2026.150216_b0170","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jdiacomp.2013.01.004","article-title":"Diabetes mellitus and incidence and mortality of kidney cancer: a meta-analysis","volume":"27","author":"Bao","year":"2013","journal-title":"J Diabetes Complications."},{"issue":"16","key":"10.1016\/j.gene.2026.150216_b0175","doi-asserted-by":"crossref","first-page":"6527","DOI":"10.1158\/0008-5472.CAN-09-4167","article-title":"Occupational trichloroethylene exposure and renal carcinoma risk: evidence of genetic susceptibility by reductive metabolism gene variants","volume":"70","author":"Moore","year":"2010","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.gene.2026.150216_b0180","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/ijc.28093","article-title":"Analgesic use and the risk of kidney cancer: a meta-analysis of epidemiologic studies","volume":"134","author":"Choueiri","year":"2014","journal-title":"Int J Cancer."},{"issue":"5","key":"10.1016\/j.gene.2026.150216_b0185","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/joim.20079","article-title":"Non-steroidal anti-inflammatory drugs and risk of kidney cancer: A Swedish nationwide cohort study in the general and high-use populations","volume":"297","author":"Wadstr\u00f6m","year":"2025","journal-title":"J Intern Med."},{"issue":"3","key":"10.1016\/j.gene.2026.150216_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102311","article-title":"Effect of NSAID Consumption on Renal Cell Carcinoma Prognosis: A Population-Based Study","volume":"23","author":"Kemppinen","year":"2025","journal-title":"Clin Genitourin Cancer."},{"key":"10.1016\/j.gene.2026.150216_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2021.102036","article-title":"Analgesic use and the risk of renal cell carcinoma - Findings from the Consortium for the Investigation of Renal Malignancies (CONFIRM) study","volume":"75","author":"Bruinsma","year":"2021","journal-title":"Cancer Epidemiol."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0200","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1053\/j.semdp.2023.11.003","article-title":"von Hippel-Lindau disease-related neoplasia with an emphasis on renal manifestations","volume":"41","author":"Tekin","year":"2024","journal-title":"Semin Diagn Pathol."},{"issue":"8","key":"10.1016\/j.gene.2026.150216_b0205","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1016\/j.acra.2024.01.034","article-title":"World Health Organization 2022 Classification Update: Radiologic and Pathologic Features of Papillary Renal Cell Carcinomas","volume":"31","author":"Shen","year":"2024","journal-title":"Acad Radiol."},{"issue":"3","key":"10.1016\/j.gene.2026.150216_b0210","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00428-024-03865-x","article-title":"Contemporary review of papillary renal cell carcinoma-current state and future directions","volume":"485","author":"Castillo","year":"2024","journal-title":"Virchows Arch."},{"issue":"6","key":"10.1016\/j.gene.2026.150216_b0215","first-page":"537","article-title":"Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors","volume":"10","author":"Delahunt","year":"1997","journal-title":"Mod Pathol."},{"issue":"6","key":"10.1016\/j.gene.2026.150216_b0220","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/his.15042","article-title":"ABCC2 brush-border expression predicts outcome in papillary renal cell carcinoma: a multi-institutional study of 254 cases","volume":"83","author":"Castillo","year":"2023","journal-title":"Histopathology."},{"issue":"6","key":"10.1016\/j.gene.2026.150216_b0225","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/s41379-021-00990-9","article-title":"Papillary renal cell carcinoma: a single institutional study of 199 cases addressing classification, clinicopathologic and molecular features, and treatment outcome","volume":"35","author":"Murugan","year":"2022","journal-title":"Mod Pathol."},{"issue":"4","key":"10.1016\/j.gene.2026.150216_b0230","first-page":"187","article-title":"New insights in the new WHO classification of adult renal tumors","volume":"67","author":"Hes","year":"2022","journal-title":"Cesk Patol."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0235","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.pathol.2020.09.015","article-title":"Chromophobe renal cell carcinoma: current and controversial issues","volume":"53","author":"Moch","year":"2021","journal-title":"Pathology."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0240","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12894-025-01816-5","article-title":"Chromophobe renal cell carcinoma - a rare kidney cancer with limited therapy options: a narrative review","volume":"25","author":"Pashai Fakhri","year":"2025","journal-title":"BMC Urol."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajur.2021.11.010","article-title":"Chromophobe renal cell carcinoma: Novel molecular insights and clinicopathologic updates","volume":"9","author":"Alaghehbandan","year":"2022","journal-title":"Asian J Urol."},{"issue":"10","key":"10.1016\/j.gene.2026.150216_b0250","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.176743","article-title":"Molecular underpinnings of dedifferentiation and aggressiveness in chromophobe renal cell carcinoma","volume":"9","author":"Kapur","year":"2024","journal-title":"JCI Insight."},{"issue":"10","key":"10.1016\/j.gene.2026.150216_b0255","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41581-022-00598-5","article-title":"Principles of human and mouse nephron development","volume":"18","author":"Schnell","year":"2022","journal-title":"Nat Rev Nephrol."},{"key":"10.1016\/j.gene.2026.150216_b0260","unstructured":"Kazi AM, Hashmi MF. Glomerulonephritis. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2025, StatPearls Publishing LLC.; 2025."},{"issue":"7","key":"10.1016\/j.gene.2026.150216_b0265","first-page":"1113","article-title":"MIRD Pamphlet No 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney","volume":"44","author":"Bouchet","year":"2003","journal-title":"J Nucl Med."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0270","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1002\/j.2040-4603.2022.tb00204.x","article-title":"Anatomophysiology of the Henle's Loop: Emphasis on the Thick Ascending Limb","volume":"12","author":"Marcoux","year":"2021","journal-title":"Compr Physiol."},{"key":"10.1016\/j.gene.2026.150216_b0275","unstructured":"Madrazo-Ibarra A, Vaitla P. Histology, Nephron. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2025, StatPearls Publishing LLC.; 2025."},{"issue":"7970","key":"10.1016\/j.gene.2026.150216_b0280","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41586-023-05769-3","article-title":"An atlas of healthy and injured cell states and niches in the human kidney","volume":"619","author":"Lake","year":"2023","journal-title":"Nature."},{"issue":"24","key":"10.1016\/j.gene.2026.150216_b0285","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2103240118","article-title":"Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response","volume":"118","author":"Zhang","year":"2021","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"7","key":"10.1016\/j.gene.2026.150216_b0290","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.trecan.2018.05.003","article-title":"Tracing Renal Cell Carcinomas back to the Nephron","volume":"4","author":"Lindgren","year":"2018","journal-title":"Trends Cancer."},{"issue":"12","key":"10.1016\/j.gene.2026.150216_b0295","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15123207","article-title":"Recent Advances in the Management of Clear Cell Renal Cell Carcinoma: Novel Biomarkers and Targeted Therapies","volume":"15","author":"Schiavoni","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.gene.2026.150216_b0300","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.943583","article-title":"Cellular milieu in clear cell renal cell carcinoma","volume":"12","author":"Raghubar","year":"2022","journal-title":"Front Oncol."},{"issue":"6","key":"10.1016\/j.gene.2026.150216_b0305","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.celrep.2017.07.043","article-title":"Cell-Type-Specific Gene Programs of the Normal Human Nephron Define Kidney Cancer Subtypes","volume":"20","author":"Lindgren","year":"2017","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0310","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41467-021-27660-3","article-title":"Single-cell chromatin accessibility landscape in kidney identifies additional cell-of-origin in heterogenous papillary renal cell carcinoma","volume":"13","author":"Wang","year":"2022","journal-title":"Nat Commun."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0315","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eururo.2020.03.003","article-title":"Next-generation RNA Sequencing-based Biomarker Characterization of Chromophobe Renal Cell Carcinoma and Related Oncocytic Neoplasms","volume":"78","author":"Skala","year":"2020","journal-title":"Eur Urol."},{"issue":"11","key":"10.1016\/j.gene.2026.150216_b0320","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/nrneph.2016.133","article-title":"Precision medicine from the renal cancer genome","volume":"12","author":"Riazalhosseini","year":"2016","journal-title":"Nat Rev Nephrol."},{"key":"10.1016\/j.gene.2026.150216_b0325","doi-asserted-by":"crossref","unstructured":"Mitchell TJ, Turajlic S, Rowan A, Nicol D, Farmery JHR, O'Brien T, et al. Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal. Cell. 2018;173(3):611-23.e17.","DOI":"10.1016\/j.cell.2018.02.020"},{"issue":"9","key":"10.1016\/j.gene.2026.150216_b0330","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41585-019-0211-5","article-title":"The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications","volume":"16","author":"Linehan","year":"2019","journal-title":"Nat Rev Urol."},{"issue":"10","key":"10.1016\/j.gene.2026.150216_b0335","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41591-020-1093-z","article-title":"Targeting the HIF2-VEGF axis in renal cell carcinoma","volume":"26","author":"Choueiri","year":"2020","journal-title":"Nat Med."},{"key":"10.1016\/j.gene.2026.150216_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.155964","article-title":"Insights into the impact of chromosome 3p mutations in advanced renal cell carcinoma treated with immune-based combinations or targeted therapy: A single-center experience","volume":"270","author":"Rosellini","year":"2025","journal-title":"Pathol Res Pract."},{"key":"10.1016\/j.gene.2026.150216_b0345","article-title":"Chromosome 3p Loss-Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma","volume":"36(36):Jco2018792549","author":"Hsieh","year":"2018","journal-title":"J Clin Oncol."},{"issue":"2","key":"10.1016\/j.gene.2026.150216_b0350","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/10668969241256111","article-title":"Clear Cell Renal Cell Carcinoma: A Comprehensive Review of its Histopathology, Genetics, and Differential Diagnosis","volume":"33","author":"Nezami","year":"2025","journal-title":"Int J Surg Pathol."},{"issue":"4","key":"10.1016\/j.gene.2026.150216_b0355","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.kint.2024.12.003","article-title":"Mutations in tumor suppressor genes Vhl and Rassf1a cause DNA damage, chromosomal instability and induce gene expression changes characteristic of clear cell renal cell carcinoma","volume":"107","author":"Catalano","year":"2025","journal-title":"Kidney Int."},{"key":"10.1016\/j.gene.2026.150216_b0360","article-title":"Optical genome and epigenome mapping of clear cell renal cell carcinoma. NAR","volume":"7(1):zcaf008","author":"Margalit","year":"2025","journal-title":"Cancer."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0365","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41419-025-07623-y","article-title":"Loss of VHL-mediated pRb regulation promotes clear cell renal cell carcinoma","volume":"16","author":"Akuma","year":"2025","journal-title":"Cell Death Dis."},{"issue":"20","key":"10.1016\/j.gene.2026.150216_b0370","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26209979","article-title":"Von Hippel-Lindau\/Hypoxia Inducible Factor Axis in Glioblastoma","volume":"26","author":"Flores","year":"2025","journal-title":"Int J Mol Sci."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0375","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00018-024-05537-0","article-title":"HIF-1 and HIF-2 in cancer: structure, regulation, and therapeutic prospects","volume":"82","author":"Shi","year":"2025","journal-title":"Cell Mol Life Sci."},{"key":"10.1016\/j.gene.2026.150216_b0380","doi-asserted-by":"crossref","unstructured":"Oxburgh L. The Extracellular Matrix Environment of Clear Cell Renal Cell Carcinoma. Cancers (Basel). 2022;14(17).","DOI":"10.3390\/cancers14174072"},{"issue":"2","key":"10.1016\/j.gene.2026.150216_b0385","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1582-4934.2010.01238.x","article-title":"Two sides to every story: the HIF-dependent and HIF-independent functions of pVHL","volume":"15","author":"Li","year":"2011","journal-title":"J Cell Mol Med."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0390","doi-asserted-by":"crossref","DOI":"10.3390\/genes16010006","article-title":"Hypoxia-Inducible Factor in Renal Cell Carcinoma: From Molecular Insights to Targeted Therapies","volume":"16","author":"Roviello","year":"2024","journal-title":"Genes (Basel)."},{"issue":"9","key":"10.1016\/j.gene.2026.150216_b0395","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.tibs.2012.06.004","article-title":"Passing the baton: the HIF switch","volume":"37","author":"Koh","year":"2012","journal-title":"Trends Biochem Sci."},{"issue":"4","key":"10.1016\/j.gene.2026.150216_b0400","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.immuni.2014.09.008","article-title":"HIF transcription factors, inflammation, and immunity","volume":"41","author":"Palazon","year":"2014","journal-title":"Immunity."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0405","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41574-018-0096-z","article-title":"The role of hypoxia-inducible factors in metabolic diseases","volume":"15","author":"Gonzalez","year":"2018","journal-title":"Nat Rev Endocrinol."},{"issue":"3","key":"10.1016\/j.gene.2026.150216_b0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15586\/jkcvhl.v12i3.413","article-title":"Hypoxia Inducible Factor-2\u03b1 (HIF-2\u03b1) Pathway Inhibitors","volume":"12","author":"Dogra","year":"2025","journal-title":"J Kidney Cancer VHL."},{"key":"10.1016\/j.gene.2026.150216_b0415","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3389\/fonc.2018.00214","article-title":"Hypoxia-Inducible Factor 2-Dependent Pathways Driving Von Hippel-Lindau-Deficient Renal Cancer","volume":"8","author":"Mel\u00e9ndez-Rodr\u00edguez","year":"2018","journal-title":"Front Oncol."},{"issue":"3","key":"10.1016\/j.gene.2026.150216_b0420","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-023-00848-6","article-title":"Targeting hypoxia-inducible factors: therapeutic opportunities and challenges","volume":"23","author":"Yuan","year":"2024","journal-title":"Nat Rev Drug Discov."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0425","doi-asserted-by":"crossref","first-page":"17642","DOI":"10.1038\/s41598-020-74631-7","article-title":"HIF1\u03b1 is not a target of 14q deletion in clear cell renal cancer","volume":"10","author":"Shenoy","year":"2020","journal-title":"Sci Rep."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0430","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1038\/s41467-020-17873-3","article-title":"HIF-1\u03b1 and HIF-2\u03b1 differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice","volume":"11","author":"Hoefflin","year":"2020","journal-title":"Nat Commun."},{"issue":"3","key":"10.1016\/j.gene.2026.150216_b0435","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1158\/2159-8290.CD-11-0098","article-title":"Genetic and functional studies implicate HIF1\u03b1 as a 14q kidney cancer suppressor gene","volume":"1","author":"Shen","year":"2011","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.gene.2026.150216_b0440","article-title":"Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel-Lindau-Disease-Associated Tumors","volume":"11","author":"Su\u00e1rez","year":"2023","journal-title":"Med Sci (Basel)"},{"issue":"11","key":"10.1016\/j.gene.2026.150216_b0445","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/modpathol.2011.107","article-title":"Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis","volume":"24","author":"Monzon","year":"2011","journal-title":"Mod Pathol."},{"key":"10.1016\/j.gene.2026.150216_b0450","doi-asserted-by":"crossref","unstructured":"Turajlic S, Xu H, Litchfield K, Rowan A, Chambers T, Lopez JI, et al. Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. Cell. 2018;173(3):581-94.e12.","DOI":"10.1016\/j.cell.2018.03.057"},{"issue":"8","key":"10.1016\/j.gene.2026.150216_b0455","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/cncr.27947","article-title":"Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma","volume":"119","author":"Kroeger","year":"2013","journal-title":"Cancer."},{"issue":"4","key":"10.1016\/j.gene.2026.150216_b0460","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.eururo.2015.08.007","article-title":"Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer","volume":"69","author":"Sch\u00f6del","year":"2016","journal-title":"Eur Urol."},{"issue":"2","key":"10.1016\/j.gene.2026.150216_b0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15586\/jkcvhl.v8i2.170","article-title":"Hypoxia-Inducible Factor-2\u03b1 as a Novel Target in Renal Cell Carcinoma","volume":"8","author":"Choi","year":"2021","journal-title":"J Kidney Cancer VHL."},{"issue":"9","key":"10.1016\/j.gene.2026.150216_b0470","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s11864-023-01106-y","article-title":"Targeting HIF-2 Alpha in Renal Cell Carcinoma","volume":"24","author":"Ahmed","year":"2023","journal-title":"Curr Treat Options Oncol."},{"issue":"12","key":"10.1016\/j.gene.2026.150216_b0475","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1016\/j.celrep.2017.02.074","article-title":"The SWI\/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma","volume":"18","author":"Nargund","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.gene.2026.150216_b0480","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.712765","article-title":"Mutational Analysis of PBRM1 and Significance of PBRM1 Mutation in Anti-PD-1 Immunotherapy of Clear Cell Renal Cell Carcinoma","volume":"11","author":"Aili","year":"2021","journal-title":"Front Oncol."},{"issue":"7","key":"10.1016\/j.gene.2026.150216_b0485","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1074\/jbc.M116.746875","article-title":"Individual Bromodomains of Polybromo-1 Contribute to Chromatin Association and Tumor Suppression in Clear Cell Renal Carcinoma","volume":"292","author":"Porter","year":"2017","journal-title":"J Biol Chem."},{"key":"10.1016\/j.gene.2026.150216_b0490","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.humpath.2022.07.022","article-title":"The expanding role of BAP1 in clear cell renal cell carcinoma","volume":"133","author":"Kapur","year":"2023","journal-title":"Hum Pathol."},{"issue":"2","key":"10.1016\/j.gene.2026.150216_b0495","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1470-2045(12)70584-3","article-title":"Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation","volume":"14","author":"Kapur","year":"2013","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.gene.2026.150216_b0500","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/PPO.0b013e3182a102d1","article-title":"PBRM1 and BAP1 as novel targets for renal cell carcinoma","volume":"19","author":"Brugarolas","year":"2013","journal-title":"Cancer J."},{"issue":"4","key":"10.1016\/j.gene.2026.150216_b0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107146","article-title":"Cancer-associated polybromo-1 bromodomain 4 missense variants variably impact bromodomain ligand binding and cell growth suppression","volume":"300","author":"Bursch","year":"2024","journal-title":"J Biol Chem."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0510","doi-asserted-by":"crossref","first-page":"5800","DOI":"10.1038\/s41467-019-13608-1","article-title":"PBRM1 acts as a p53 lysine-acetylation reader to suppress renal tumor growth","volume":"10","author":"Cai","year":"2019","journal-title":"Nat Commun."},{"issue":"4","key":"10.1016\/j.gene.2026.150216_b0515","first-page":"341","article-title":"A Scoping Review of Population Diversity in the Common Genomic Aberrations of Clear Cell Renal Cell Carcinoma","volume":"103","author":"Kumar","year":"2025","journal-title":"Oncology."},{"issue":"8","key":"10.1016\/j.gene.2026.150216_b0520","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1093\/nar\/gkad072","article-title":"PBRM1 bromodomains associate with RNA to facilitate chromatin association","volume":"51","author":"De Silva","year":"2023","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.gene.2026.150216_b0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104294","article-title":"The genomic landscape of metastatic clear-cell renal cell carcinoma and its prognostic value: a comprehensive analysis of a large real-world clinico-genomic database","volume":"10","author":"Rizzo","year":"2025","journal-title":"ESMO Open."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0530","doi-asserted-by":"crossref","DOI":"10.1080\/15592294.2025.2456418","article-title":"Deciphering the interplay between SETD2 mediated H3K36me3 and RNA N6-methyladenosine in clear cell renal cell carcinoma (ccRCC)","volume":"20","author":"Shaikh","year":"2025","journal-title":"Epigenetics."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0535","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41419-020-2266-x","article-title":"SETD2 mutation in renal clear cell carcinoma suppress autophagy via regulation of ATG12","volume":"11","author":"Gonz\u00e1lez-Rodr\u00edguez","year":"2020","journal-title":"Cell Death Dis."},{"issue":"31","key":"10.1016\/j.gene.2026.150216_b0540","doi-asserted-by":"crossref","first-page":"50719","DOI":"10.18632\/oncotarget.9368","article-title":"SETD2: an epigenetic modifier with tumor suppressor functionality","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget."},{"issue":"4","key":"10.1016\/j.gene.2026.150216_b0545","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.154120","article-title":"SETD2 regulates chromatin accessibility and transcription to suppress lung tumorigenesis","volume":"8","author":"Xie","year":"2023","journal-title":"JCI Insight."},{"issue":"7","key":"10.1016\/j.gene.2026.150216_b0550","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.21037\/tau-24-20","article-title":"Combination of PARP and DNA methylation inhibitors as a potential personalized therapy for SETD2-mutated clear-cell renal cancers","volume":"13","author":"Shahini","year":"2024","journal-title":"Transl Androl Urol."},{"key":"10.1016\/j.gene.2026.150216_b0555","series-title":"Lymphoma","article-title":"Histone Methyltransferase SETD2 in Lymphoid Malignancy","author":"Li","year":"2021"},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0560","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13059-025-03483-z","article-title":"SETD2 loss-of-function uniquely sensitizes cells to epigenetic targeting of NSD1-directed H3K36 methylation","volume":"26","author":"Wagner","year":"2025","journal-title":"Genome Biol."},{"key":"10.1016\/j.gene.2026.150216_b0565","article-title":"Histone methyltransferase SETD2: An epigenetic driver in clear cell renal cell carcinoma","volume":"13","author":"Yu","year":"2023","journal-title":"Front Oncol."},{"issue":"6","key":"10.1016\/j.gene.2026.150216_b0570","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.21037\/tau-2025-177","article-title":"Gene profiling and clinicopathological features for prognostic modeling of recurrence in non-metastatic clear-cell renal cell carcinoma","volume":"14","author":"Yan","year":"2025","journal-title":"Transl Androl Urol."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0575","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/1878-0261.13487","article-title":"SETD2 loss in renal epithelial cells drives epithelial-to-mesenchymal transition in a TGF-\u03b2-independent manner","volume":"18","author":"Wang","year":"2024","journal-title":"Mol Oncol."},{"issue":"4","key":"10.1016\/j.gene.2026.150216_b0580","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/s12276-023-00979-1","article-title":"BAP1 as a guardian of genome stability: implications in human cancer","volume":"55","author":"Kwon","year":"2023","journal-title":"Exp Mol Med."},{"issue":"10","key":"10.1016\/j.gene.2026.150216_b0585","doi-asserted-by":"crossref","DOI":"10.3390\/genes13101703","article-title":"Intrinsic Disorder in BAP1 and Its Association with Uveal Melanoma","volume":"13","author":"Djulbegovic","year":"2022","journal-title":"Genes (Basel)."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0590","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41420-021-00406-2","article-title":"Emerging multifaceted roles of BAP1 complexes in biological processes","volume":"7","author":"Szczepanski","year":"2021","journal-title":"Cell Death Discov."},{"issue":"48","key":"10.1016\/j.gene.2026.150216_b0595","doi-asserted-by":"crossref","first-page":"28643","DOI":"10.1074\/jbc.M115.661553","article-title":"The BAP1\/ASXL2 Histone H2A Deubiquitinase Complex Regulates Cell Proliferation and Is Disrupted in Cancer","volume":"290","author":"Daou","year":"2015","journal-title":"J Biol Chem."},{"issue":"11","key":"10.1016\/j.gene.2026.150216_b0600","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1158\/0008-5472.CAN-20-3430","article-title":"Roles of the BAP1 Tumor Suppressor in Cell Metabolism","volume":"81","author":"Han","year":"2021","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.gene.2026.150216_b0605","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/ajcp\/aqaa176","article-title":"BAP1-Mutated Clear Cell Renal Cell Carcinoma","volume":"155","author":"Gallan","year":"2021","journal-title":"Am J Clin Pathol."},{"key":"10.1016\/j.gene.2026.150216_b0610","doi-asserted-by":"crossref","unstructured":"Minardi D, Lucarini G, Milanese G, Di Primio R, Montironi R, Muzzonigro G. Loss of nuclear BAP1 protein expression is a marker of poor prognosis in patients with clear cell renal cell carcinoma. Urol Oncol. 2016;34(8):338.e11-8.","DOI":"10.1016\/j.urolonc.2016.03.006"},{"issue":"8","key":"10.1016\/j.gene.2026.150216_b0615","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1158\/2159-8290.CD-17-0292","article-title":"Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade","volume":"7","author":"Gu","year":"2017","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0620","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/path.6490","article-title":"mTOR-mediated upregulation of B7-H3 in MiT\/TFE translocation renal cell carcinoma","volume":"268","author":"Li","year":"2026","journal-title":"J Pathol."},{"issue":"6","key":"10.1016\/j.gene.2026.150216_b0625","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s13402-025-01125-x","article-title":"TFE3 fusion proteins promoted the progression of Xp11.2 translocation renal cell carcinoma through post-translational modification of PDL1 by upregulating CCND1\/Cyclin D1","volume":"48","author":"Lu","year":"2025","journal-title":"Cell Oncol (Dordr)"},{"issue":"10","key":"10.1016\/j.gene.2026.150216_b0630","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0333202","article-title":"SPAG6 hypermethylation silences a novel tumor suppressor and inhibits renal cell carcinoma progression via PI3K\/AKT\/mTOR pathway","volume":"20","author":"Wu","year":"2025","journal-title":"PLoS One."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0635","doi-asserted-by":"crossref","first-page":"38656","DOI":"10.1038\/s41598-025-22561-7","article-title":"KDM6A deficiency promotes tumor progression and resistance to cabozantinib treatment in clear cell renal cell carcinoma","volume":"15","author":"Kohada","year":"2025","journal-title":"Sci Rep."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0640","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s42003-025-07695-8","article-title":"KDM5C and KDM5D mutations have different consequences in clear cell renal cell carcinoma cells","volume":"8","author":"M\u00fcller","year":"2025","journal-title":"Commun Biol."},{"issue":"2","key":"10.1016\/j.gene.2026.150216_b0645","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.cancergencyto.2010.02.013","article-title":"Cytogenetic features, clinical significance and prognostic impact of type 1 and type 2 papillary renal cell carcinoma","volume":"199","author":"Antonelli","year":"2010","journal-title":"Cancer Genet Cytogenet."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0650","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4103\/UA.UA_32_18","article-title":"Chromosomal aberrations in renal cell carcinoma: An overview with implications for clinical practice","volume":"11","author":"Quddus","year":"2019","journal-title":"Urol Ann."},{"issue":"2","key":"10.1016\/j.gene.2026.150216_b0655","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/PAP.0000000000000220","article-title":"Papillary Renal Cell Carcinoma (PRCC): An Update","volume":"26","author":"Akhtar","year":"2019","journal-title":"Adv Anat Pathol."},{"issue":"4","key":"10.1016\/j.gene.2026.150216_b0660","doi-asserted-by":"crossref","first-page":"33","DOI":"10.15586\/jkcvhl.v10i4.294","article-title":"Papillary Renal Cell Carcinoma: Demographics, Survival Analysis, Racial Disparities, and Genomic Landscape","volume":"10","author":"Ullah","year":"2023","journal-title":"J Kidney Cancer VHL."},{"issue":"2","key":"10.1016\/j.gene.2026.150216_b0665","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa1505917","article-title":"Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma","volume":"374","author":"Linehan","year":"2016","journal-title":"N Engl J Med."},{"issue":"10","key":"10.1016\/j.gene.2026.150216_b0670","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1097\/01.MP.0000090924.90762.94","article-title":"Gains of chromosomes 7, 17, 12, 16, and 20 and loss of Y occur early in the evolution of papillary renal cell neoplasia: a fluorescent in situ hybridization study","volume":"16","author":"Brunelli","year":"2003","journal-title":"Mod Pathol."},{"issue":"12","key":"10.1016\/j.gene.2026.150216_b0675","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143468","article-title":"Relationships between Chromosome 7 Gain, MET Gene Copy Number Increase and MET Protein Overexpression in Chinese Papillary Renal Cell Carcinoma Patients","volume":"10","author":"Yin","year":"2015","journal-title":"PLoS One."},{"key":"10.1016\/j.gene.2026.150216_b0680","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2024.101090","article-title":"Structure and function of the lysine methyltransferase SETD2 in cancer: From histones to cytoskeleton","volume":"59","author":"Michail","year":"2025","journal-title":"Neoplasia."},{"issue":"5","key":"10.1016\/j.gene.2026.150216_b0685","article-title":"Multiple Primary Melanoma Associated with CDKN2A Mutation-Case Report and Review of the Literature","volume":"60","author":"Nurla","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.gene.2026.150216_b0690","unstructured":"Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, et al. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep. 2018;23(1):313-26.e5."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0695","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.eururo.2017.05.033","article-title":"Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling","volume":"73","author":"Pal","year":"2018","journal-title":"Eur Urol."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0700","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/j.semdp.2023.12.002","article-title":"Hereditary papillary renal cell carcinoma","volume":"41","author":"Jacoba","year":"2024","journal-title":"Semin Diagn Pathol."},{"issue":"13","key":"10.1016\/j.gene.2026.150216_b0705","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1158\/1078-0432.CCR-13-2173","article-title":"MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array","volume":"20","author":"Albiges","year":"2014","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.gene.2026.150216_b0710","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejca.2022.04.021","article-title":"Impact of MET status on treatment outcomes in papillary renal cell carcinoma: Apooled analysis of historical data","volume":"170","author":"Albiges","year":"2022","journal-title":"Eur J Cancer."},{"issue":"6","key":"10.1016\/j.gene.2026.150216_b0715","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13061329","article-title":"Patients with Papillary Renal Cancer and Germline Duplication of MET Exons 5-21","volume":"13","author":"Mikhaylenko","year":"2025","journal-title":"Biomedicines."},{"key":"10.1016\/j.gene.2026.150216_b0720","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejca.2017.10.014","article-title":"Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial","volume":"87","author":"Sch\u00f6ffski","year":"2017","journal-title":"Eur J Cancer."},{"issue":"11","key":"10.1016\/j.gene.2026.150216_b0725","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1038\/s41388-020-01577-5","article-title":"The role of MET in chemotherapy resistance","volume":"40","author":"Wood","year":"2021","journal-title":"Oncogene."},{"issue":"9","key":"10.1016\/j.gene.2026.150216_b0730","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/nrclinonc.2017.40","article-title":"Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges","volume":"14","author":"Bradley","year":"2017","journal-title":"Nat Rev Clin Oncol."},{"key":"10.1016\/j.gene.2026.150216_b0735","doi-asserted-by":"crossref","DOI":"10.3389\/or.2025.1615111","article-title":"The role and research progress of the MET signalling pathway in targeted therapy for osteosarcoma","volume":"19","author":"Su","year":"2025","journal-title":"Oncol Rev."},{"issue":"3","key":"10.1016\/j.gene.2026.150216_b0740","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ccr.2014.07.014","article-title":"The somatic genomic landscape of chromophobe renal cell carcinoma","volume":"26","author":"Davis","year":"2014","journal-title":"Cancer Cell."},{"issue":"2","key":"10.1016\/j.gene.2026.150216_b0745","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100396","article-title":"Genetic Profiling Uncovers Genome-Wide Loss of Heterozygosity and Provides Insight into Mechanisms of Sarcomatoid Transformation in Chromophobe Renal Cell Carcinoma","volume":"37","author":"Collins","year":"2024","journal-title":"Mod Pathol."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0750","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s13046-021-02026-1","article-title":"Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1\u03b1, HIF2\u03b1, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma","volume":"40","author":"Li","year":"2021","journal-title":"J Exp Clin Cancer Res."},{"issue":"22","key":"10.1016\/j.gene.2026.150216_b0755","doi-asserted-by":"crossref","first-page":"5582","DOI":"10.1158\/1078-0432.CCR-16-0985","article-title":"Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group","volume":"22","author":"Ooms","year":"2016","journal-title":"Clin Cancer Res."},{"issue":"5","key":"10.1016\/j.gene.2026.150216_b0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100472","article-title":"High-Grade, Nonsarcomatoid Chromophobe Renal Cell Carcinoma: A Series of 22 Cases With Novel Molecular Features on a Subset","volume":"37","author":"Baraban","year":"2024","journal-title":"Mod Pathol."},{"issue":"12","key":"10.1016\/j.gene.2026.150216_b0765","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.92688","article-title":"Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma","volume":"2","author":"Casuscelli","year":"2017","journal-title":"JCI Insight."},{"issue":"6","key":"10.1016\/j.gene.2026.150216_b0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104463","article-title":"Single-cell transcriptomes underscore genetically distinct tumor characteristics and microenvironment for hereditary kidney cancers","volume":"25","author":"Jikuya","year":"2022","journal-title":"iScience."},{"issue":"3","key":"10.1016\/j.gene.2026.150216_b0775","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2025.03.012","article-title":"Renal Neoplasia in Birt-Hogg-Dub\u00e9 Syndrome: Integrated Histopathologic, Bulk, and Single-cell Transcriptomic Analysis","volume":"88","author":"Gupta","year":"2025","journal-title":"Eur Urol."},{"issue":"6","key":"10.1016\/j.gene.2026.150216_b0780","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/j.juro.2013.06.012","article-title":"Germline PTEN mutation Cowden syndrome: an underappreciated form of hereditary kidney cancer","volume":"190","author":"Shuch","year":"2013","journal-title":"J Urol."},{"issue":"7","key":"10.1016\/j.gene.2026.150216_b0785","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/PAS.0000000000000237","article-title":"Renal cell carcinoma in tuberous sclerosis complex","volume":"38","author":"Yang","year":"2014","journal-title":"Am J Surg Pathol."},{"issue":"3","key":"10.1016\/j.gene.2026.150216_b0790","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41379-021-00971-y","article-title":"Renal cell carcinoma associated with tuberous sclerosis complex (TSC)\/mammalian target of rapamycin (MTOR) genetic alterations","volume":"35","author":"Argani","year":"2022","journal-title":"Mod Pathol."},{"issue":"10","key":"10.1016\/j.gene.2026.150216_b0795","doi-asserted-by":"crossref","DOI":"10.3390\/genes12101585","article-title":"Renal Cell Carcinoma in Tuberous Sclerosis Complex","volume":"12","author":"Henske","year":"2021","journal-title":"Genes (Basel)."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0800","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2024.189240","article-title":"Kidney cancer: From tumor biology to innovative therapeutics","volume":"1880","author":"Rinaldi","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer."},{"issue":"4","key":"10.1016\/j.gene.2026.150216_b0805","doi-asserted-by":"crossref","first-page":"270","DOI":"10.25122\/jml-2025-0066","article-title":"Optimizing outcomes of partial nephrectomy in patients with tumors in solitary kidneys: a non-systematic review","volume":"18","author":"Ianiotescu","year":"2025","journal-title":"J Med Life."},{"issue":"2","key":"10.1016\/j.gene.2026.150216_b0810","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/JU.0000000000001911","article-title":"Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I","volume":"206","author":"Campbell","year":"2021","journal-title":"J Urol."},{"issue":"3","key":"10.1016\/j.gene.2026.150216_b0815","doi-asserted-by":"crossref","first-page":"740","DOI":"10.21037\/tau-2025-136","article-title":"Comparing the long-term prognosis and renal function changes of partial nephrectomy (PN) and radical nephrectomy (RN) in T1 stage renal cell carcinoma patients","volume":"14","author":"Cao","year":"2025","journal-title":"Transl Androl Urol."},{"key":"10.1016\/j.gene.2026.150216_b0820","article-title":"Comparative Effectiveness for Survival and Renal Function of Partial and Radical Nephrectomy for Localized Renal Tumors: A Systematic Review and Meta-Analysis","author":"Kim","year":"2012","journal-title":"J Urol."},{"issue":"12","key":"10.1016\/j.gene.2026.150216_b0825","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jama.2024.12848","article-title":"Renal Cell Carcinoma: A Review","volume":"332","author":"Rose","year":"2024","journal-title":"Jama."},{"issue":"3","key":"10.1016\/j.gene.2026.150216_b0830","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.euf.2025.04.001","article-title":"Management of Metastatic Renal Cell Carcinoma: Guideline Updates","volume":"11","author":"Barragan-Carrillo","year":"2025","journal-title":"Eur Urol Focus."},{"issue":"12","key":"10.1016\/j.gene.2026.150216_b0835","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26125577","article-title":"Immune Checkpoint Inhibitors in Clear Cell Renal Cell Carcinoma (ccRCC)","volume":"26","author":"Rysz","year":"2025","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.gene.2026.150216_b0840","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/978-3-031-97242-3_13","article-title":"Immunotherapy in Renal Cell Carcinoma","volume":"129","author":"Zugman","year":"2025","journal-title":"Cancer Treat Res."},{"issue":"2","key":"10.1016\/j.gene.2026.150216_b0845","first-page":"240","article-title":"Molecular aspects of renal cell carcinoma: a review","volume":"1","author":"Koul","year":"2011","journal-title":"Am J Cancer Res."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0850","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semnephrol.2019.12.004","article-title":"The Therapeutic Landscape of Renal Cell Carcinoma: From the Dark Age to the Golden Age","volume":"40","author":"Huang","year":"2020","journal-title":"Semin Nephrol."},{"issue":"3","key":"10.1016\/j.gene.2026.150216_b0855","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030793","article-title":"Complete Response in Metastatic Clear Cell Renal Cell Carcinoma Patients Treated with Immune-Checkpoint Inhibitors: Remission or Healing? How to Improve Patients' Outcomes?","volume":"15","author":"Thouvenin","year":"2023","journal-title":"Cancers (Basel)."},{"issue":"2","key":"10.1016\/j.gene.2026.150216_b0860","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0022-5347(05)67889-5","article-title":"Systemic therapy for renal cell carcinoma","volume":"163","author":"Motzer","year":"2000","journal-title":"J Urol."},{"issue":"2","key":"10.1016\/j.gene.2026.150216_b0865","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med."},{"issue":"9669","key":"10.1016\/j.gene.2026.150216_b0870","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(09)60229-4","article-title":"Renal cell carcinoma","volume":"373","author":"Rini","year":"2009","journal-title":"Lancet."},{"key":"10.1016\/j.gene.2026.150216_b0875","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fonc.2012.00013","article-title":"Third generation tyrosine kinase inhibitors and their development in advanced renal cell carcinoma","volume":"2","author":"Bukowski","year":"2012","journal-title":"Front Oncol."},{"issue":"22","key":"10.1016\/j.gene.2026.150216_b0880","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med."},{"issue":"9637","key":"10.1016\/j.gene.2026.150216_b0885","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet."},{"issue":"7","key":"10.1016\/j.gene.2026.150216_b0890","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.70167","article-title":"Targeting mTOR Kinase for Cancer Treatment: A Comprehensive Review With Clinical Insights","volume":"86","author":"Hossain","year":"2025","journal-title":"Drug Dev Res."},{"key":"10.1016\/j.gene.2026.150216_b0895","article-title":"Advances in immunotherapy and targeted therapy for advanced clear-cell renal cell carcinoma: current strategies and future directions","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol."},{"key":"10.1016\/j.gene.2026.150216_b0900","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118875","article-title":"Immune checkpoint inhibition in renal cell carcinoma: Mechanisms of resistance and emerging therapeutic strategies","volume":"193","author":"Darzi","year":"2025","journal-title":"Biomed Pharmacother."},{"issue":"14","key":"10.1016\/j.gene.2026.150216_b0905","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med."},{"issue":"12","key":"10.1016\/j.gene.2026.150216_b0910","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med."},{"issue":"14","key":"10.1016\/j.gene.2026.150216_b0915","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med."},{"issue":"9","key":"10.1016\/j.gene.2026.150216_b0920","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med."},{"issue":"8","key":"10.1016\/j.gene.2026.150216_b0925","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol."},{"issue":"4","key":"10.1016\/j.gene.2026.150216_b0930","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic Therapy for Metastatic Renal-Cell Carcinoma","volume":"376","author":"Choueiri","year":"2017","journal-title":"N Engl J Med."},{"issue":"22","key":"10.1016\/j.gene.2026.150216_b0935","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.gene.2026.150216_b0940","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251317846","article-title":"Belzutifan for the treatment of renal cell carcinoma","volume":"17","author":"Wu","year":"2025","journal-title":"Ther Adv Med Oncol."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0945","doi-asserted-by":"crossref","DOI":"10.3390\/cells13010034","article-title":"Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma","volume":"13","author":"Meng","year":"2023","journal-title":"Cells."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0950","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1038\/s41467-021-25865-0","article-title":"Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy","volume":"12","author":"Takamatsu","year":"2021","journal-title":"Nat Commun."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b0955","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12943-023-01911-x","article-title":"Evolution of cell therapy for renal cell carcinoma","volume":"23","author":"Wang","year":"2024","journal-title":"Mol Cancer."},{"issue":"6","key":"10.1016\/j.gene.2026.150216_b0960","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1080\/14737140.2022.2075347","article-title":"Developments in personalized therapy for metastatic renal cell carcinoma","volume":"22","author":"Fujiwara","year":"2022","journal-title":"Expert Rev Anticancer Ther."},{"key":"10.1016\/j.gene.2026.150216_b0965","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.2340\/1651-226X.2025.44533","article-title":"Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab","volume":"64","author":"Kheir","year":"2025","journal-title":"Acta Oncol."},{"issue":"6","key":"10.1016\/j.gene.2026.150216_b0970","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102431","volume":"23","author":"Lemelin","year":"2025","journal-title":"Clin Genitourin Cancer."},{"key":"10.1016\/j.gene.2026.150216_b0975","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2340\/1651-226X.2024.40390","article-title":"Baseline neutrophil-to-eosinophil-ratio and outcome in metastatic clear-cell renal cell carcinoma treated with nivolumab or ipilimumab\/nivolumab","volume":"63","author":"Beulque","year":"2024","journal-title":"Acta Oncol."},{"issue":"9","key":"10.1016\/j.gene.2026.150216_b0980","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/iju.70144","article-title":"Current Evidences and Future Perspectives in the Management of Metastatic Non-Clear Cell Renal Cell Carcinoma","volume":"32","author":"Nakanishi","year":"2025","journal-title":"Int J Urol."},{"key":"10.1016\/j.gene.2026.150216_b0985","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104985","article-title":"Chromophobe renal cell carcinoma: Emerging vulnerabilities as a promise for a new therapeutic landscape","volume":"216","author":"Salem","year":"2025","journal-title":"Crit Rev Oncol Hematol."},{"issue":"22","key":"10.1016\/j.gene.2026.150216_b0990","doi-asserted-by":"crossref","DOI":"10.3390\/cells14221781","article-title":"Recent Advances in nccRCC Classification and Therapeutic Approaches","volume":"14","author":"Wang","year":"2025","journal-title":"Cells."},{"key":"10.1016\/j.gene.2026.150216_b0995","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102881","article-title":"Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma","volume":"133","author":"Santoni","year":"2025","journal-title":"Cancer Treat Rev."},{"issue":"7","key":"10.1016\/j.gene.2026.150216_b1000","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/1535-7163.MCT-17-1299","article-title":"Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies","volume":"17","author":"Makhov","year":"2018","journal-title":"Mol Cancer Ther."},{"issue":"10","key":"10.1016\/j.gene.2026.150216_b1005","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17101613","article-title":"Molecular Mechanisms of Drug Resistance in Clear Cell Renal Cell Carcinoma","volume":"17","author":"Bianchi","year":"2025","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.gene.2026.150216_b1010","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.657639","article-title":"Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice","volume":"11","author":"Roberto","year":"2021","journal-title":"Front Oncol."},{"issue":"12","key":"10.1016\/j.gene.2026.150216_b1015","doi-asserted-by":"crossref","DOI":"10.1002\/cpz1.70282","article-title":"Overview of Preclinical Drug-Resistant Tumor Models and Their Application in Drug Discovery","volume":"5","author":"Li","year":"2025","journal-title":"Curr Protoc."},{"issue":"4","key":"10.1016\/j.gene.2026.150216_b1020","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00109-020-01990-z","article-title":"Cancer research using organoid technology","volume":"99","author":"Kretzschmar","year":"2021","journal-title":"J Mol Med (Berl)."},{"issue":"9","key":"10.1016\/j.gene.2026.150216_b1025","first-page":"e1874","article-title":"Evaluating cancer cell line and patient-derived xenograft recapitulation of tumor and non-diseased tissue gene expression profiles in silico","volume":"6","author":"Williams","year":"2023","journal-title":"Cancer Rep (Hoboken)."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b1030","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13059-025-03650-2","article-title":"Direct genetic transformation bypasses tumor-associated DNA methylation alterations","volume":"26","author":"Hetzel","year":"2025","journal-title":"Genome Biol."},{"key":"10.1016\/j.gene.2026.150216_b1035","doi-asserted-by":"crossref","unstructured":"Gunti S, Hoke ATK, Vu KP, London NR, Jr. Organoid and Spheroid Tumor Models: Techniques and Applications. Cancers (Basel). 2021;13(4).","DOI":"10.3390\/cancers13040874"},{"issue":"7244","key":"10.1016\/j.gene.2026.150216_b1040","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nature07935","article-title":"Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche","volume":"459","author":"Sato","year":"2009","journal-title":"Nature."},{"issue":"2","key":"10.1016\/j.gene.2026.150216_b1045","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41591-024-03489-3","article-title":"Clinical applications of human organoids","volume":"31","author":"Verstegen","year":"2025","journal-title":"Nat Med."},{"issue":"23","key":"10.1016\/j.gene.2026.150216_b1050","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17233850","article-title":"Pancreatic Cancer Organoids: Modeling Disease and Guiding Therapy","volume":"17","author":"Morceau","year":"2025","journal-title":"Cancers (Basel)."},{"issue":"4","key":"10.1016\/j.gene.2026.150216_b1055","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2018100300","article-title":"Long-term expanding human airway organoids for disease modeling","volume":"38","author":"Sachs","year":"2019","journal-title":"Embo j."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b1060","doi-asserted-by":"crossref","first-page":"25185","DOI":"10.1038\/s41598-025-07816-7","article-title":"Applications and research trends in organoid based infectious disease models","volume":"15","author":"Ryu","year":"2025","journal-title":"Sci Rep."},{"issue":"7568","key":"10.1016\/j.gene.2026.150216_b1065","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature14966","article-title":"Single-cell messenger RNA sequencing reveals rare intestinal cell types","volume":"525","author":"Gr\u00fcn","year":"2015","journal-title":"Nature."},{"issue":"3","key":"10.1016\/j.gene.2026.150216_b1070","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41556-020-0472-5","article-title":"Fast and efficient generation of knock-in human organoids using homology-independent CRISPR-Cas9 precision genome editing","volume":"22","author":"Artegiani","year":"2020","journal-title":"Nat Cell Biol."},{"issue":"5","key":"10.1016\/j.gene.2026.150216_b1075","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12050695","article-title":"Patient-Derived Organoids of Colorectal Cancer: A Useful Tool for Personalized Medicine","volume":"12","author":"Kiwaki","year":"2022","journal-title":"J Pers Med."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b1080","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/cei\/uxad118","article-title":"Organoids as a tool to study homeostatic and pathological immune-epithelial interactions in the gut","volume":"218","author":"Kromann","year":"2024","journal-title":"Clin Exp Immunol."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b1085","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12943-025-02429-0","article-title":"The application of organoids in treatment decision-making for digestive system cancers: progress and challenges","volume":"24","author":"Wang","year":"2025","journal-title":"Mol Cancer."},{"issue":"9","key":"10.1016\/j.gene.2026.150216_b1090","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1073\/pnas.1222878110","article-title":"Genomic responses in mouse models poorly mimic human inflammatory diseases","volume":"110","author":"Seok","year":"2013","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b1095","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41420-025-02407-x","article-title":"Tumor organoid-immune co-culture models: exploring a new perspective of tumor immunity","volume":"11","author":"Wang","year":"2025","journal-title":"Cell Death Discov."},{"issue":"14","key":"10.1016\/j.gene.2026.150216_b1100","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22147667","article-title":"The Use of Stem Cell-Derived Organoids in Disease Modeling: An Update","volume":"22","author":"Azar","year":"2021","journal-title":"Int J Mol Sci."},{"issue":"2","key":"10.1016\/j.gene.2026.150216_b1105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcb.2025.151496","article-title":"Self-organization and applications of neural organoids","volume":"104","author":"Sakaguchi","year":"2025","journal-title":"Eur J Cell Biol."},{"key":"10.1016\/j.gene.2026.150216_b1110","doi-asserted-by":"crossref","DOI":"10.1186\/s13287-025-04865-7","article-title":"Modeling pathogenesis and progression of metabolic dysfunction-associated steatotic liver disease and therapeutic drug screening using hESC-derived mature polarized hepatocyte organoids","author":"Qin","year":"2025","journal-title":"Stem Cell Res Ther."},{"key":"10.1016\/j.gene.2026.150216_b1115","doi-asserted-by":"crossref","DOI":"10.1016\/j.envint.2025.109940","article-title":"Aged microplastics disrupted copper homeostasis to induce vascular toxicity: in vivo and human vascular organoids-based in vitro study","volume":"206","author":"Chen","year":"2025","journal-title":"Environ Int."},{"key":"10.1016\/j.gene.2026.150216_b1120","doi-asserted-by":"crossref","DOI":"10.1177\/20417314251397594","article-title":"IPSC-derived organoid-sourced skin cells enable functional 3D skin modeling of recessive dystrophic epidermolysis bullosa","volume":"16","author":"Garriga-Cerda","year":"2025","journal-title":"J Tissue Eng."},{"key":"10.1016\/j.gene.2026.150216_b1125","doi-asserted-by":"crossref","DOI":"10.1007\/7651_2025_684","article-title":"Transcription Factor Driven Generation of Vascular Organoids from Induced Pluripotent Stem Cells","author":"Leung","year":"2025","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.gene.2026.150216_b1130","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1692333","article-title":"Endocrine-disrupting effects of environmental BPS and PFOS on human brain organoid development","volume":"16","author":"Di Credico","year":"2025","journal-title":"Front Endocrinol (Lausanne)."},{"key":"10.1016\/j.gene.2026.150216_b1135","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2025.1680376","article-title":"Establishment and transcriptomic characterization of canine organoids from multiple tissues","volume":"13","author":"Zdyrski","year":"2025","journal-title":"Front Cell Dev Biol."},{"key":"10.1016\/j.gene.2026.150216_b1140","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1718911","article-title":"Complementary strategies in pancreatic cancer precision medicine: therapeutic prediction and immune modulation","volume":"15","author":"Lee","year":"2025","journal-title":"Front Oncol."},{"issue":"12","key":"10.1016\/j.gene.2026.150216_b1145","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.jvir.2025.08.038","article-title":"Facilitating Personalized Immunotherapy with Interventional Radiology and Tumor Organoids","volume":"36","author":"Tian","year":"2025","journal-title":"J Vasc Interv Radiol."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b1150","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1038\/s41467-019-11867-6","article-title":"Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening","volume":"10","author":"Kim","year":"2019","journal-title":"Nat Commun."},{"key":"10.1016\/j.gene.2026.150216_b1155","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.18489","article-title":"Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening","volume":"5","author":"Verissimo","year":"2016","journal-title":"Elife."},{"issue":"10","key":"10.1016\/j.gene.2026.150216_b1160","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1007\/s11427-024-2888-8","article-title":"Endocrine cancer organoids in basic and translational medical research","volume":"68","author":"Chen","year":"2025","journal-title":"Sci China Life Sci."},{"issue":"12","key":"10.1016\/j.gene.2026.150216_b1165","doi-asserted-by":"crossref","DOI":"10.3390\/curroncol32120653","article-title":"High-Throughput 3D Bioprinted Organoids of Skin Cancer Utilized for Diagnosis and Personalized Therapy","volume":"32","author":"Shukla","year":"2025","journal-title":"Curr Oncol."},{"key":"10.1016\/j.gene.2026.150216_b1170","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2025.214528","article-title":"From 3D culture to clinical decision-making: Systematic innovations in breast cancer organoids","volume":"179","author":"Hu","year":"2026","journal-title":"Biomater Adv."},{"key":"10.1016\/j.gene.2026.150216_b1175","article-title":"Modeling the human bladder tissue using three dimensional in vitro approaches as a tool for drug screening platforms","author":"Carvalho","year":"2025","journal-title":"Acta Biomater"},{"issue":"8","key":"10.1016\/j.gene.2026.150216_b1180","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00109-023-02340-5","article-title":"Esophageal organoids: applications and future prospects","volume":"101","author":"Liu","year":"2023","journal-title":"J Mol Med (Berl)."},{"issue":"11","key":"10.1016\/j.gene.2026.150216_b1185","doi-asserted-by":"crossref","DOI":"10.5306\/wjco.v16.i11.110453","article-title":"Gastric organoids: A promising model for studying \u201cinflammation-cancer\u201d transition in atrophic gastritis","volume":"16","author":"Liu","year":"2025","journal-title":"World J Clin Oncol."},{"issue":"4","key":"10.1016\/j.gene.2026.150216_b1190","doi-asserted-by":"crossref","DOI":"10.3892\/or.2021.8177","article-title":"Development of patient\u2011derived tumor organoids and a drug testing model for renal cell carcinoma","volume":"46","author":"Kazama","year":"2021","journal-title":"Oncol Rep."},{"issue":"12","key":"10.1016\/j.gene.2026.150216_b1195","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7432","article-title":"The establishment of kidney cancer organoid line in drug testing","volume":"13","author":"Tse","year":"2024","journal-title":"Cancer Medicine."},{"issue":"6","key":"10.1016\/j.gene.2026.150216_b1200","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/s12276-023-01010-3","article-title":"piRNA-1742 promotes renal cell carcinoma malignancy by regulating USP8 stability through binding to hnRNPU and thereby inhibiting MUC12 ubiquitination","volume":"55","author":"Zhang","year":"2023","journal-title":"Exp Mol Med."},{"issue":"5","key":"10.1016\/j.gene.2026.150216_b1205","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1158\/0008-5472.CAN-22-1693","article-title":"YAP-Activated SATB2 Is a Coactivator of NRF2 That Amplifies Antioxidative Capacity and Promotes Tumor Progression in Renal Cell Carcinoma","volume":"83","author":"Jin","year":"2023","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b1210","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12943-025-02457-w","article-title":"Lipid reprogramming and ferroptosis crosstalk in clear cell renal cell carcinoma: metabolic vulnerabilities and therapeutic targeting","volume":"24","author":"Deng","year":"2025","journal-title":"Mol Cancer."},{"issue":"2","key":"10.1016\/j.gene.2026.150216_b1215","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.semnephrol.2018.01.006","article-title":"Metabolomics and Metabolic Reprogramming in Kidney Cancer","volume":"38","author":"Weiss","year":"2018","journal-title":"Semin Nephrol."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b1220","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13046-023-02713-1","article-title":"Therapeutic targeting of P2X4 receptor and mitochondrial metabolism in clear cell renal carcinoma models","volume":"42","author":"Rupert","year":"2023","journal-title":"J Exp Clin Cancer Res."},{"issue":"6","key":"10.1016\/j.gene.2026.150216_b1225","doi-asserted-by":"crossref","first-page":"e883","DOI":"10.1002\/ctm2.883","article-title":"Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma","volume":"12","author":"Reustle","year":"2022","journal-title":"Clin Transl Med."},{"key":"10.1016\/j.gene.2026.150216_b1230","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2025.1664292","article-title":"Emerging roles of metabolic biomarkers in renal cell carcinoma: from molecular mechanisms to clinical implications","volume":"13","author":"Yang","year":"2025","journal-title":"Front Cell Dev Biol."},{"key":"10.1016\/j.gene.2026.150216_b1235","doi-asserted-by":"crossref","unstructured":"Mitochondrial complex I promotes kidney cancer metastasis. Nature. 2024;633(8031):923-31.","DOI":"10.1038\/s41586-024-07812-3"},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b1240","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s11060-025-05248-x","article-title":"Emerging therapies for glioblastoma","volume":"176","author":"Sarfraz","year":"2025","journal-title":"J Neurooncol."},{"key":"10.1016\/j.gene.2026.150216_b1245","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104621","article-title":"Preclinical models of soft tissue sarcomas - generation and applications to enhance translational research","volume":"207","author":"Pasquali","year":"2025","journal-title":"Crit Rev Oncol Hematol."},{"issue":"7","key":"10.1016\/j.gene.2026.150216_b1250","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s12094-021-02774-8","article-title":"Phenotypical screening on metastatic PRCC-TFE3 fusion translocation renal cell carcinoma organoids reveals potential therapeutic agents","volume":"24","author":"Cao","year":"2022","journal-title":"Clin Transl Oncol."},{"issue":"4","key":"10.1016\/j.gene.2026.150216_b1255","doi-asserted-by":"crossref","DOI":"10.1088\/1758-5090\/adecc5","article-title":"Bioprinting of patient-derived heterogeneous renal cell carcinoma organoids for personalized therapy","volume":"17","author":"Mao","year":"2025","journal-title":"Biofabrication."},{"issue":"7","key":"10.1016\/j.gene.2026.150216_b1260","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.970","article-title":"Patient-derived renal cell carcinoma organoids for personalized cancer therapy","volume":"12","author":"Li","year":"2022","journal-title":"Clinical and Translational Medicine."},{"key":"10.1016\/j.gene.2026.150216_b1265","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.3389\/fonc.2020.01775","article-title":"Cultivation of Clear Cell Renal Cell Carcinoma Patient-Derived Organoids in an Air-Liquid Interface System as a Tool for Studying Individualized Therapy","volume":"10","author":"Esser","year":"2020","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b1270","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-025-06949-7","article-title":"Renal cell carcinoma organoids for precision medicine: bridging the gap between models and patients","volume":"23","author":"Gao","year":"2025","journal-title":"Journal of Translational Medicine."},{"issue":"14","key":"10.1016\/j.gene.2026.150216_b1275","doi-asserted-by":"crossref","DOI":"10.1172\/JCI176230","article-title":"Molecular analysis of primary and metastatic sites in patients with renal cell carcinoma","volume":"134","author":"Gulati","year":"2024","journal-title":"Journal of Clinical Investigation."},{"issue":"8","key":"10.1016\/j.gene.2026.150216_b1280","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.7150\/thno.55424","article-title":"Downregulated METTL14 accumulates BPTF that reinforces super-enhancers and distal lung metastasis via glycolytic reprogramming in renal cell carcinoma","volume":"11","author":"Zhang","year":"2021","journal-title":"Theranostics."},{"key":"10.1016\/j.gene.2026.150216_b1285","article-title":"Tumor microenvironment-driven drug resistance in urologic cancers: mechanisms and therapeutic targets. Genes","author":"Yang","year":"2025","journal-title":"Genomics."},{"issue":"9","key":"10.1016\/j.gene.2026.150216_b1290","article-title":"Tumor Microenvironment and Its Role in Cancer Progression: An Integrative Review","volume":"17","author":"Almazrouei","year":"2025","journal-title":"Cureus."},{"issue":"12","key":"10.1016\/j.gene.2026.150216_b1295","doi-asserted-by":"crossref","DOI":"10.3390\/curroncol32120680","article-title":"Patient-Derived Organoids as a Platform to Decipher and Overcome Radioresistance: From the Tumor Microenvironment to Radiosensitizer Discovery","volume":"32","author":"Yin","year":"2025","journal-title":"Curr Oncol."},{"key":"10.1016\/j.gene.2026.150216_b1300","doi-asserted-by":"crossref","unstructured":"Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, et al. Organoid Modeling of the Tumor Immune Microenvironment. Cell. 2018;175(7):1972-88.e16.","DOI":"10.1016\/j.cell.2018.11.021"},{"key":"10.1016\/j.gene.2026.150216_b1305","doi-asserted-by":"crossref","unstructured":"Rashidan K, Ayadilord M, Hazrati A, Nazerian A, Shafiee A, Hashemi SM. Immune and Immune-Integrated Organoids as NextGeneration Platforms for Disease Modeling. MedComm (2020). 2025;6(12):e70531.","DOI":"10.1002\/mco2.70531"},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b1310","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189514","article-title":"Organoids as a new approach in advancing cancer therapies for hematologic malignancies","volume":"1881","author":"Wisal","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer."},{"key":"10.1016\/j.gene.2026.150216_b1315","doi-asserted-by":"crossref","unstructured":"Li K, Liu C, Sui X, Li C, Zhang T, Zhao T, et al. An organoid co-culture model for probing systemic anti-tumor immunity in lung cancer. Cell Stem Cell. 2025;32(8):1218-34.e7.","DOI":"10.1016\/j.stem.2025.05.011"},{"issue":"4","key":"10.1016\/j.gene.2026.150216_b1320","doi-asserted-by":"crossref","DOI":"10.3390\/cells12040628","article-title":"Secretome of Stromal Cancer-Associated Fibroblasts (CAFs): Relevance in Cancer","volume":"12","author":"Mishra","year":"2023","journal-title":"Cells."},{"issue":"12","key":"10.1016\/j.gene.2026.150216_b1325","article-title":"Patient-derived tumor organoid and fibroblast assembloid models for interrogation of the tumor microenvironment in esophageal adenocarcinoma","volume":"4","author":"Sharpe","year":"2024","journal-title":"Cell Rep Methods."},{"issue":"14","key":"10.1016\/j.gene.2026.150216_b1330","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17142287","article-title":"Patient-Derived Gastric Cancer Assembloid Model Integrating Matched Tumor Organoids and Stromal Cell Subpopulations","volume":"17","author":"Shapira-Netanelov","year":"2025","journal-title":"Cancers (Basel)."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b1335","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s44164-025-00084-9","article-title":"Colorectal carcinoma organoid and cancer-associated fibroblasts co-culture system for drug evaluation","volume":"4","author":"Wang","year":"2025","journal-title":"In Vitro Model."},{"issue":"2","key":"10.1016\/j.gene.2026.150216_b1340","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2025.114656","article-title":"Constructing a co-culture model of cancer-associated fibroblasts and ovarian cancer organoids and studying mechanisms of drug resistance","volume":"450","author":"Ma","year":"2025","journal-title":"Exp Cell Res."},{"issue":"11","key":"10.1016\/j.gene.2026.150216_b1345","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112610","article-title":"Control of Tumor Progression by Angiocrine Factors","volume":"13","author":"Alsina-Sanchis","year":"2021","journal-title":"Cancers (Basel)."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b1350","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1186\/s12964-025-02441-3","article-title":"Crosstalk between tumor endothelial cells and cancer cells is important for metastasis initiation","volume":"23","author":"Oria","year":"2025","journal-title":"Cell Commun Signal."},{"key":"10.1016\/j.gene.2026.150216_b1355","first-page":"813","article-title":"Bioengineering an improved three-dimensional vascularized co-culture model for studying Neuron-Microglia interactions","volume":"54","author":"Han","year":"2025","journal-title":"Bioact Mater."},{"issue":"4","key":"10.1016\/j.gene.2026.150216_b1360","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s10544-025-00773-y","article-title":"Engineering vascularized brain tumor organoids: bridging the gap between models and reality","volume":"27","author":"Hariri","year":"2025","journal-title":"Biomed Microdevices."},{"issue":"6","key":"10.1016\/j.gene.2026.150216_b1365","article-title":"Bioengineering methods for vascularizing organoids","volume":"4","author":"Nwokoye","year":"2024","journal-title":"Cell Rep Methods."},{"key":"10.1016\/j.gene.2026.150216_b1370","doi-asserted-by":"crossref","unstructured":"do Amaral SR, Atanasov AP, de Souza DCM, de Paiva IF, Ferreira ML, Grover LM, et al. 3D bioprinted melanoma models: a novel paradigm for the assessment of anticancer strategies combining PDT and drug delivery systems. Biomed Eng Online. 2025;24(1):132.","DOI":"10.1186\/s12938-025-01476-4"},{"key":"10.1016\/j.gene.2026.150216_b1375","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.715093","article-title":"HiPS-Endothelial Cells Acquire Cardiac Endothelial Phenotype in Co-culture With hiPS-Cardiomyocytes","volume":"9","author":"Helle","year":"2021","journal-title":"Front Cell Dev Biol."},{"key":"10.1016\/j.gene.2026.150216_b1380","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.76707","article-title":"Generation of vascularized brain organoids to study neurovascular interactions","volume":"11","author":"Sun","year":"2022","journal-title":"Elife."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b1385","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/s41467-024-45710-4","article-title":"A microfluidic platform integrating functional vascularized organoids-on-chip","volume":"15","author":"Quintard","year":"2024","journal-title":"Nat Commun."},{"key":"10.1016\/j.gene.2026.150216_b1390","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121639","article-title":"Advances in 3D bioprinting of tissues\/organs for regenerative medicine and in-vitro models","volume":"287","author":"Jain","year":"2022","journal-title":"Biomaterials."},{"issue":"2","key":"10.1016\/j.gene.2026.150216_b1395","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/ndt\/gfae177","article-title":"Biology of the proximal tubule in body homeostasis and kidney disease","volume":"40","author":"Hoenig","year":"2025","journal-title":"Nephrol Dial Transplant."},{"issue":"7","key":"10.1016\/j.gene.2026.150216_b1400","doi-asserted-by":"crossref","first-page":"e970","DOI":"10.1002\/ctm2.970","article-title":"Patient-derived renal cell carcinoma organoids for personalized cancer therapy","volume":"12","author":"Li","year":"2022","journal-title":"Clin Transl Med."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b1405","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s12943-025-02420-9","article-title":"ACOX2 destabilizes the MRE11-RAD50-NBS1 complex and boosts anticancer immunity via the cGAS-STING pathway in clear cell renal cell carcinoma","volume":"24","author":"Ye","year":"2025","journal-title":"Mol Cancer."},{"issue":"4","key":"10.1016\/j.gene.2026.150216_b1410","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1101\/gr.279345.124","article-title":"Heterogeneous and novel transcript expression in single cells of patient-derived clear cell renal cell carcinoma organoids","volume":"35","author":"Karakulak","year":"2025","journal-title":"Genome Res."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b1415","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s13046-025-03534-0","article-title":"O-GlcNAcylation of UBAP2L regulates stress granule formation and sunitinib resistance in clear cell renal cell carcinoma","volume":"44","author":"Xing","year":"2025","journal-title":"J Exp Clin Cancer Res."},{"issue":"12","key":"10.1016\/j.gene.2026.150216_b1420","doi-asserted-by":"crossref","first-page":"e7432","DOI":"10.1002\/cam4.7432","article-title":"The establishment of kidney cancer organoid line in drug testing","volume":"13","author":"Tse","year":"2024","journal-title":"Cancer Medicine."},{"key":"10.1016\/j.gene.2026.150216_b1425","article-title":"Patient-derived organoids potentiate precision medicine in advanced clear cell renal cell carcinoma. Precis","volume":"5(4):pbac028","author":"Xue","year":"2022","journal-title":"Clin Med."},{"issue":"12","key":"10.1016\/j.gene.2026.150216_b1430","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.2215\/CJN.05920613","article-title":"Distal convoluted tubule","volume":"9","author":"Subramanya","year":"2014","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b1435","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/j.2040-4603.2015.tb00597.x","article-title":"Distal convoluted tubule","volume":"5","author":"McCormick","year":"2015","journal-title":"Compr Physiol."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b1440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biocel.2010.10.006","article-title":"The renal connecting tubule: Resolved and unresolved issues in Ca(2+) transport","volume":"43","author":"Markadieu","year":"2011","journal-title":"Int J Biochem Cell Biol."},{"issue":"6","key":"10.1016\/j.gene.2026.150216_b1445","first-page":"555","article-title":"Connecting tubules develop from the tip of the ureteric bud in the human kidney","volume":"156","author":"Sarkany","year":"2021","journal-title":"Histochem Cell Biol."},{"key":"10.1016\/j.gene.2026.150216_b1450","unstructured":"McMahon RS, Penfold D, Bashir K. Anatomy, Abdomen and Pelvis: Kidney Collecting Ducts. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2025, StatPearls Publishing LLC.; 2025."},{"issue":"1","key":"10.1016\/j.gene.2026.150216_b1455","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2215\/CJN.05760513","article-title":"Collecting duct principal cell transport processes and their regulation","volume":"10","author":"Pearce","year":"2015","journal-title":"Clin J Am Soc Nephrol."},{"issue":"2","key":"10.1016\/j.gene.2026.150216_b1460","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2215\/CJN.08880914","article-title":"Collecting duct intercalated cell function and regulation","volume":"10","author":"Roy","year":"2015","journal-title":"Clin J Am Soc Nephrol."},{"issue":"3","key":"10.1016\/j.gene.2026.150216_b1465","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1002\/j.2040-4603.2012.tb00446.x","article-title":"Structure and function of the thin limbs of the loop of Henle","volume":"2","author":"Pannabecker","year":"2012","journal-title":"Compr Physiol."}],"container-title":["Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037811192600226X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037811192600226X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T08:04:29Z","timestamp":1780128269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S037811192600226X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":293,"alternative-id":["S037811192600226X"],"URL":"https:\/\/doi.org\/10.1016\/j.gene.2026.150216","relation":{},"ISSN":["0378-1119"],"issn-type":[{"value":"0378-1119","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renal Cell Carcinoma: Histopathology, Molecular Features, and the Emerging Role of Organoid Models","name":"articletitle","label":"Article Title"},{"value":"Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gene.2026.150216","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"150216"}}